object
describ
characterist
evolut
patient
bronchiol
admit
pediatr
intens
care
unit
compar
treatment
preand
postpubl
acut
bronchiol
ab
common
caus
lower
respiratori
tract
infect
nurs
infant
hospit
admiss
infant
one
year
age
respiratori
syncyti
viru
rsv
frequent
causal
microorgan
though
mani
other
also
caus
disord
differ
degre
sever
acut
bronchiol
character
first
episod
breath
difficulti
nurs
infant
month
age
preced
upper
airway
infect
commonli
occur
epidem
period
consensu
lack
regard
clinic
definit
acut
bronchiol
children
studi
admiss
rate
attribut
disord
scarc
though
report
patient
acut
bronchiol
requir
hospit
admiss
requir
admiss
pediatr
intens
care
unit
picu
though
figur
reach
popul
associ
risk
factor
therapeut
measur
establish
efficaci
applic
acut
bronchiol
avail
mani
studi
describ
great
variabl
patient
manag
treatment
mere
support
adopt
conserv
manag
approach
seem
adequ
children
particularli
youngest
patient
fact
case
evolv
favor
time
independ
chosen
treatment
option
probabl
explain
still
use
certain
drug
demonstr
clinic
benefit
base
profession
institut
prefer
bronchiol
gener
import
problem
sinc
drug
treatment
shown
littl
help
current
guid
recommend
drug
treatment
restrict
case
result
widespread
variabl
refer
overand
undertreat
evalu
adher
intern
recommend
import
respect
bronchiol
constitut
challeng
gener
manag
patient
specif
treatment
ventilatori
support
present
studi
compris
epidemiolog
analysi
studi
clinic
characterist
treatment
outcom
patient
sever
acut
respiratori
failur
secondari
bronchiol
requir
admiss
picu
hand
comparison
made
two
time
period
public
clinic
practic
guid
cpg
american
academi
pediatr
aap
determin
whether
new
recommend
follow
unit
post
hoc
descript
observ
studi
carri
involv
retrospect
analysi
prospect
databas
patient
one
year
age
sever
acut
bronchiol
admit
picu
tertiari
hospit
period
septemb
septemb
hospit
refer
center
bed
cover
hospit
patient
region
spanish
autonom
commun
bronchiol
diagnos
base
classic
criteria
sole
exclus
criterion
exclud
infant
parent
inform
consent
inclus
databas
could
obtain
year
unit
creat
prospect
registri
patient
diagnos
bronchiol
enter
data
dissoci
order
ensur
patient
anonym
access
databas
control
mean
password
epidemiolog
clinic
microbiolog
inform
collect
patient
gender
age
upon
admiss
origin
comorbid
prematur
exprematur
infant
gestat
week
bronchopulmonari
dysplasia
base
need
oxygen
therapi
day
congenit
heart
diseas
neurolog
disord
pediatr
risk
score
mortal
iii
prismiii
bronchiol
score
sant
joan
de
deu
brosjod
caus
acut
respiratori
failur
treatment
receiv
respiratori
inotrop
support
need
invas
devic
durat
admiss
picu
global
hospit
stay
mortal
nasopharyng
aspir
obtain
patient
polymeras
chain
reaction
pcr
test
respiratori
virus
routin
procedur
unit
microbiolog
laboratori
determin
presenc
rsv
rhinoviru
metapneumoviru
viru
influenza
parainfluenza
adenoviru
coronaviru
enteroviru
well
bordetella
pertussi
parapertussi
context
invas
bacteri
infect
consid
presenc
pneumonia
urinari
tract
infect
sepsi
defin
accord
intern
guid
confirm
case
includ
nosocomi
bronchiol
regard
bronchiol
manifest
patient
admit
hospit
h
time
diagnosi
rest
case
consid
correspond
communityacquir
bronchiol
includ
blood
urin
cerebrospin
fluid
csf
cultur
sampl
case
patient
suspect
bacteri
infect
nasopharyng
tracheal
aspir
patient
suspect
bacteri
pneumonia
consist
chest
xray
find
fever
c
creactiv
protein
mgdl
andor
procalcitonin
ngml
comparison
made
describ
data
correspond
two
defin
period
accord
modif
patient
manag
protocol
hospit
fig
base
recommend
cpg
aap
diagnosi
manag
prevent
bronchiol
modif
aap
guid
includ
bronchodil
test
salbutamol
patient
month
age
predomin
wheez
order
limit
use
respond
decreas
point
sever
scale
restrict
adrenalin
spray
use
sever
case
admit
picu
rescu
therapi
hyperton
salin
solut
hss
diluent
bronchodil
therapi
isol
basi
intens
secretori
patient
respond
medic
indic
corticotherapi
case
postextub
croup
croup
prevent
patient
subject
intub
day
infect
due
rhinoviru
guid
present
gener
session
depart
hospit
includ
institut
intranet
likewis
email
sent
healthcar
profession
inform
mention
chang
qualit
variabl
express
frequenc
percentag
quantit
variabl
report
mean
standard
deviat
sd
median
interquartil
rang
iqr
applic
comparison
qualit
variabl
base
chisquar
test
quantit
variabl
compar
use
student
ttest
mann
whitney
utest
depend
whether
data
exhibit
normal
distribut
otherwis
statist
signific
consid
p
spss
version
statist
packag
use
throughout
studi
approv
clinic
research
ethic
committe
institut
abid
recommend
declar
helsinki
latest
edit
fortaleza
brazil
studi
includ
total
patient
acut
bronchiol
male
median
age
day
iqr
day
total
patient
healthi
nurs
infant
prematur
document
case
heart
diseas
lung
diseas
four
neurolog
disord
subject
patient
receiv
immunoprophylaxi
palivizumab
patient
histori
prematur
patient
sever
heart
diseas
inhal
h
score
hfo
lkgmin
previou
protocol
therapeut
test
made
inhal
salbutamol
adrenalin
patient
use
hss
contempl
picu
admiss
rate
among
patient
report
emerg
servic
diagnos
bronchiol
case
bronchiol
admiss
picu
correspond
communityacquir
diseas
case
nosocomi
origin
onehalf
case
came
hospit
ward
case
patient
origin
detail
tabl
median
sever
score
brosjod
point
iqr
median
prismiii
score
iqr
respiratori
syncyti
viru
caus
bronchiol
patient
follow
rhinoviru
metapneumoviru
patient
respect
viral
coinfect
record
case
common
combin
rsv
rhinoviru
follow
rsv
coronaviru
etiolog
studi
summar
tabl
total
patient
receiv
treatment
inhal
hss
treatment
receiv
describ
tabl
postextub
croup
rate
empir
antibiot
therapi
start
case
patient
due
suspect
infect
case
therapi
start
due
confirm
infect
mean
global
durat
antibiot
treatment
day
day
sampl
blood
cultur
collect
patient
urin
cultur
patient
lumbar
punctur
csf
sampl
perform
case
bacteri
infect
confirm
patient
correspond
sepsi
total
pneumonia
urinari
tract
infect
total
case
consid
correspond
communityacquir
bronchiol
rest
regard
nosocomi
present
diseas
patient
tabl
noninvas
ventil
niv
requir
patient
cpap
bipap
main
indic
niv
breath
difficulti
case
patient
indic
correspond
clinic
manifest
apnea
endotrach
intub
convent
mechan
ventil
prove
necessari
patient
median
total
durat
ventil
day
iqr
patient
admit
picu
median
day
iqr
day
inotrop
support
prove
necessari
patient
mean
durat
day
frequent
use
drug
dopamin
extracorpor
membran
oxygen
ecmo
requir
patient
lastli
two
patient
die
due
bronchiol
one
period
one
case
death
occur
secondari
concomit
type
herp
infect
fatal
consequ
bronchiol
due
adenoviru
viral
septic
shock
progress
multiorgan
failur
tabl
first
period
involv
patient
second
patient
contrast
two
period
statist
signific
differ
observ
term
patient
age
gender
presenc
comorbid
origin
etiolog
bronchiol
second
period
brosjod
sever
score
seen
higher
median
versu
point
though
differ
fail
reach
statist
signific
case
viral
coinfect
significantli
greater
figur
record
second
group
p
therefor
affirm
group
quit
homogen
compar
term
tabl
administr
inhal
salbutamol
similar
period
inhal
adrenalin
use
preval
second
period
versu
p
way
hss
versu
p
treatment
corticosteroid
versu
p
though
latter
case
statist
signific
reach
fewer
patient
intub
second
period
versu
p
though
latter
character
greater
number
patient
niv
versu
p
tabl
indic
antibiot
treatment
also
decreas
second
period
versu
first
period
p
compar
two
period
durat
antibiot
treatment
significantli
shorter
second
period
p
patient
second
period
receiv
antibiot
treatment
fewer
day
experienc
clinic
worsen
requir
longer
admiss
picu
variabl
mortal
nitric
oxid
administr
extracorpor
membran
oxygen
durat
stay
picu
global
hospit
admiss
inotrop
drug
support
similar
group
tabl
acut
bronchiol
common
remain
great
challeng
healthcar
profession
accord
review
literatur
consist
result
patient
bronchiol
requir
hospit
admiss
must
admit
picu
respiratori
syncyti
viru
remain
lead
caus
bronchiol
evidenc
publish
review
follow
rhinoviru
distanc
virus
metapneumoviru
influenza
viru
coronaviru
consist
observ
viral
coinfect
neglig
phenomenon
may
impli
poorer
cours
diseas
tendenc
toward
longer
hospit
stay
follow
public
cpg
aap
updat
protocol
refer
indic
nebul
although
guid
restrict
inhal
therapi
use
adrenalin
hss
seriou
case
contempl
new
guidelin
maintain
salbutamol
patient
month
age
respond
well
treatment
even
though
contempl
mention
new
guid
princip
inhal
treatment
studi
hss
use
consid
recommend
aap
view
probabl
mucociliari
cleans
action
though
indirect
support
evid
avail
contraposit
recent
articl
publish
zhang
et
al
appear
evid
effect
use
hss
although
inhal
adrenalin
recommend
ground
evidenc
improv
outcom
patient
bronchiol
still
administ
almost
onehalf
patient
sinc
afford
degre
symptom
improv
also
observ
studi
increas
adrenalin
use
second
time
period
attribut
increas
patient
sever
sinc
score
differ
scale
differ
significantli
though
tendenc
toward
increas
niv
use
lesser
applic
invas
mechan
ventil
albeit
without
statist
signific
differ
one
hypothes
adrenalin
use
due
increas
use
niv
sinc
inhal
adrenalin
employ
intub
patient
though
discard
administr
drug
rescu
patient
avoid
need
intub
extens
studi
need
order
confirm
accord
literatur
corticosteroid
therapi
would
indic
though
classic
use
patient
spastic
auscult
find
one
year
age
protocol
corticosteroid
administ
patient
postextub
croup
repres
seri
croup
prophylaxi
day
mechan
ventil
patient
rhinoviru
isol
causal
organ
rhinoviru
case
second
period
treat
corticosteroid
sinc
appear
use
studi
found
literatur
despit
modif
protocol
observ
decreas
corticosteroid
use
patient
diagnos
bronchiol
indic
therefor
reconsid
unit
case
view
sever
patient
bronchiol
requir
admiss
picu
moreov
tend
younger
age
gener
three
month
intub
mechan
ventil
impli
longer
stay
increas
risk
complic
reduct
treatment
administr
complic
issu
emerg
primari
care
set
probabl
area
increas
adher
recommend
cpg
aap
would
observ
addit
import
rememb
complex
problem
pose
definit
use
result
classif
manag
difficulti
report
bacteri
infect
rate
among
patient
bronchiol
requir
admiss
picu
rang
consist
find
incid
drop
case
analyz
set
emerg
care
hospit
ward
consequ
also
usual
impli
lesser
use
antibiot
reason
antibiot
treatment
patient
acut
respiratori
failur
remain
high
concern
possibl
presenc
undetect
bacteri
infect
antibiot
treatment
rate
seri
high
particularli
consid
patient
final
diagnos
bacteri
infect
nevertheless
observ
rate
similar
report
studi
conduct
picu
set
recent
studi
shein
et
al
justifi
antibiot
treatment
first
two
day
intub
among
patient
sever
bronchiol
ground
reduc
mean
durat
stay
studi
compar
two
time
period
observ
clear
decreas
indic
antibiot
treatment
togeth
reduct
durat
treatment
probabl
due
chang
bronchiol
manag
protocol
line
recommend
aap
also
implement
antibiot
treatment
optim
program
picu
cours
second
half
year
adopt
program
seek
improv
clinic
outcom
ensur
minimum
toxic
decreas
develop
resist
case
sever
bronchiol
high
antibiot
treatment
rate
observ
studi
literatur
gener
probabl
requir
adopt
strategi
earli
suspens
treatment
well
deescal
measur
accordingli
clear
need
diagnost
tool
refer
invas
bacteri
infect
sinc
sign
symptom
unspecif
difficult
distinguish
viral
condit
use
biomark
procalcitonin
could
help
discrimin
system
inflammatori
respons
gener
viral
infect
bacteri
overinfect
thu
allow
individu
indic
durat
antibiot
treatment
seri
patient
second
period
receiv
antibiot
treatment
fewer
day
experi
clinic
worsen
requir
longer
picu
stay
earli
deescal
therefor
seem
safe
practic
singlecent
natur
studi
constitut
limit
assess
chang
protocol
follow
public
intern
recommend
studi
design
analyz
practic
unit
point
futur
improv
howev
due
larg
number
patient
involv
studi
allow
accept
comparison
two
patient
sampl
two
contempl
time
period
bronchiol
gener
mani
admiss
among
nurs
infant
one
year
age
know
epidemiolog
clinic
microbiolog
data
evolut
time
allow
us
analyz
adher
intern
patient
manag
guid
identifi
weak
strong
point
protocol
use
local
level
difficulti
strictli
appli
recommend
aap
patient
sever
bronchiol
modifi
manag
protocol
deepli
root
tradit
clinic
practic
revis
indic
corticosteroid
therapi
inhalatori
treatment
sever
bronchiol
probabl
need
dr
carmina
guitart
conduct
initi
data
collect
analysi
draft
review
manuscript
approv
final
version
dr
carm
alejandr
conceiv
design
studi
conduct
initi
data
collect
analysi
draft
review
manuscript
approv
final
version
dr
isabel
torru
conduct
data
collect
draft
review
manuscript
approv
final
version
dr
balagu
analyz
interpret
data
review
manuscript
approv
final
version
dr
elisabeth
esteban
analyz
interpret
data
review
manuscript
approv
final
version
dr
francisco
cambra
analyz
interpret
data
review
manuscript
approv
final
version
dr
iolanda
jordan
conceiv
design
studi
conduct
initi
data
collect
analysi
perform
statist
analysi
draft
review
manuscript
approv
final
version
